Midcap Value Alert: 3 Years of Subscription at the Price of 1
Here is the latest financial fact sheet of LYKA LABS. For more details, see the LYKA LABS quarterly results and LYKA LABS share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | 0.4 |
No. of shares | m | 33.09 |
1 Week | % | -6.3 |
1 Month | % | -11.3 |
1 Year | % | 14.8 |
52 week H/L | Rs | 143.5/89.0 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
LYKA LABS EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 52 | 35 | 36 | 267 | 202 | |
Low | Rs | 21 | 10 | 13 | 25 | 100 | |
Sales per share (Unadj.) | Rs | 25.2 | 21.4 | 30.1 | 67.6 | 30.3 | |
Earnings per share (Unadj.) | Rs | -2.3 | -21.8 | -3.5 | 13.4 | -4.3 | |
Diluted earnings per share | Rs | -1.9 | -18.9 | -3.0 | 11.6 | -4.0 | |
Cash flow per share (Unadj.) | Rs | 0.3 | -19.0 | -0.6 | 19.4 | 0.3 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Avg Dividend yield | % | 0 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | 15.0 | -5.0 | -9.0 | 4.6 | 9.1 | |
Adj. book value per share | Rs | 12.8 | -4.3 | -7.8 | 4.0 | 8.5 | |
Shares outstanding (eoy) | m | 28.14 | 28.69 | 28.69 | 28.69 | 30.69 | |
Price / Sales ratio | x | 1.5 | 1.0 | 0.8 | 2.2 | 5.0 | |
Avg P/E ratio | x | -16.3 | -1.0 | -6.9 | 10.9 | -35.2 | |
P/CF ratio (eoy) | x | 107.4 | -1.2 | -39.3 | 7.5 | 465.7 | |
Price / Book Value ratio | x | 2.4 | -4.5 | -2.7 | 31.4 | 16.5 | |
Dividend payout | % | 0 | 0 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 1,033 | 645 | 694 | 4,189 | 4,634 | |
Total wages/salary | Rs m | 147 | 139 | 146 | 181 | 186 |
LYKA LABS INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 708 | 615 | 863 | 1,941 | 931 | |
Other income | Rs m | 21 | 31 | 16 | 21 | 34 | |
Total revenues | Rs m | 729 | 646 | 878 | 1,962 | 965 | |
Gross profit | Rs m | -30 | -369 | 186 | 946 | 94 | |
Depreciation | Rs m | 73 | 80 | 83 | 173 | 141 | |
Interest | Rs m | 72 | 201 | 259 | 201 | 119 | |
Profit before tax | Rs m | -154 | -619 | -141 | 592 | -132 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | -91 | 7 | -41 | 208 | 0 | |
Profit after tax | Rs m | -64 | -626 | -101 | 384 | -132 | |
Gross profit margin | % | -4.3 | -60.0 | 21.5 | 48.8 | 10.1 | |
Effective tax rate | % | 58.8 | -1.2 | 28.7 | 35.1 | 0.1 | |
Net profit margin | % | -9.0 | -101.8 | -11.7 | 19.8 | -14.1 |
LYKA LABS BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 351 | 359 | 291 | 522 | 442 | |
Current liabilities | Rs m | 848 | 663 | 499 | 994 | 326 | |
Net working cap to sales | % | -70.2 | -49.5 | -24.1 | -24.3 | 12.5 | |
Current ratio | x | 0.4 | 0.5 | 0.6 | 0.5 | 1.4 | |
Inventory Days | Days | 149 | 116 | 87 | 41 | 90 | |
Debtors Days | Days | 754 | 477 | 367 | 347 | 789 | |
Net fixed assets | Rs m | 1,677 | 1,520 | 1,446 | 1,334 | 1,073 | |
Share capital | Rs m | 281 | 287 | 287 | 287 | 307 | |
"Free" reserves | Rs m | 141 | -430 | -545 | -154 | -27 | |
Net worth | Rs m | 423 | -143 | -258 | 133 | 280 | |
Long term debt | Rs m | 793 | 1,261 | 1,514 | 625 | 638 | |
Total assets | Rs m | 2,029 | 1,879 | 1,737 | 1,856 | 1,515 | |
Interest coverage | x | -1.2 | -2.1 | 0.5 | 3.9 | -0.1 | |
Debt to equity ratio | x | 1.9 | -8.8 | -5.9 | 4.7 | 2.3 | |
Sales to assets ratio | x | 0.3 | 0.3 | 0.5 | 1.0 | 0.6 | |
Return on assets | % | 0.4 | -22.6 | 9.1 | 31.6 | -0.8 | |
Return on equity | % | -15.0 | 436.5 | 39.1 | 288.2 | -47.0 | |
Return on capital | % | -6.8 | -37.4 | 9.4 | 104.7 | -1.4 | |
Exports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx outflow | Rs m | 0 | 0 | 0 | 0 | 0 | |
Net fx | Rs m | 0 | 0 | 0 | 0 | 0 |
LYKA LABS CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 267 | 53 | 88 | 792 | 90 | |
From Investments | Rs m | -40 | -1 | -2 | -62 | 74 | |
From Financial Activity | Rs m | -234 | 34 | -118 | -632 | -216 | |
Net Cashflow | Rs m | -7 | 86 | -31 | 99 | -53 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Babulal Jain | COMP SEC: Kishore P Shah | YEAR OF INC: 1976 | BSE CODE: 500259 | FV (Rs): 10 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare LYKA LABS With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Asian share markets made a cautious start on Monday in a week where inflation figures could make or break hopes for earlier US rate cuts.